To expedite development of vaccines that protect against the Coronavirus Disease COVID-19 caused by the SARS-CoV-2 virus, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will expand an existing partnership with New Jersey-based Janssen Research & Development, part of Johnson & Johnson.
Janssen and the Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will share research and development costs and expertise to help accelerate Janssen’s investigational novel coronavirus vaccine into clinical evaluation.
“When it comes to infectious diseases, vaccines are the backbone of the public health response,” said BARDA Director Rick A. Bright, Ph.D. “With emerging infectious diseases such as COVID-19, speed is crucial to saving lives and reducing further spread of the virus. Janssen is a proven partner with a flexible, rapid, vaccine platform which gives us an edge in the race to protect people in the U.S. and worldwide from the health security threat posed by this novel coronavirus.”
Janssen also will work on the scale-up of production and manufacturing capacities required to manufacture the candidate vaccine. This same approach was used to develop and manufacture Janssen’s investigational Ebola vaccine with BARDA support; that vaccine is being used in the Democratic Republic of the Congo as part of the current Ebola outbreak response.
In addition to an investigational Ebola vaccine, the BARDA and Janssen partnership has supported development of other products and technologies to help save lives in public health emergencies, including a treatment for blood injuries caused by acute levels of radiation and a treatment for injuries caused by inhaled sulfur mustard. The partnership also has supported two JLABS respiratory protection technology innovation challenges and established a health security innovation zone at the new JLABS@Washington DC facility to spur breakthrough technologies needed for health security.
There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.